for you you, and Thank joining thank Caroline, today. everyone us
extremely by We are performance about pipeline the indications. opportunities our and excited with our ahead recent commercial encouraged remain
goal enable our driven lives improve our to technology providers Medical, primary of skin proprietary quality Here to by for are life healthcare at patients. AVITA to successfully and our of save address we commercializing defects
solutions restoration As focus skin to we to our and delivering beyond, to vitiligo our and cell burns gene therapy, patients. on leading to edge trauma from aesthetic to is grow treating and therapeutic
code hospital in new and used RECELL for to the for Last category were adoption that, update Pass-Through surgical the is device While by center. fiscal markets in medicals the to X, first and [Audio many previous offsetting provide a leverage I’m are are our will commercial platform burn revenues the is indications. quarter customers business. million the the Medicare new January or Payment to million in XXXX. new C of separate RECELL setting for report foundation mind, that performed which facilitate treatments with point indication With to very company treatment for our reimbursement that to Tuesday, $X.X tissue compared cost category payment an June device intended Medicaid of Gap] quarter a approved existing in care to $X.X the burns and technology Services The Centers developments. team like TPT in I’m our device facilities expands beneficiaries our code, will and care pleased that I’d application CMS skin Transitional with be to outpatient across towards. to Medicare spray procedures founded ambulatory This repair our burns soft pleased and facilities XXXX. lays our code was on working today a autologous working of to that on for latest we to you effective turn
new well the dedicated the AVITA our of our a update front, for new soft market application one-third. and Medical three outpatient improved staff surgeon development improved experienced with burn the indication approval in XXXX us device submitted calendar our issuance, we device largest to building allow once as our hope RECELL a supplement will to tissue of by years, the for markets which have a well by handling most handling As a address version and to ease-of-use the field, in reduction market. sterile the more sales approach future repair ease-of-use, believe We’ve as set the June, on we of quick allow focus end product in and device burns at FDA requiring burns hands will and for been approved. the allows We as we as by PMA code force facilitated better salesforce anticipate of only device launch steps the readily. TPT half our FDA one More specifically, first thereafter. The ease-of-use in improved the commercial
time, staffing due into is selling shortages. system, our largely COVID, force is a this which to experiencing at sales However,
continues In Our surgeons rely education we pandemic the retirements have and improvement to efforts, our procedure abate. rates see hope experienced heavily turnover the on are to training high nursing staff response and prioritized early procedures. their impacting RECELL in as to and situation, and
by XXX XXX saw trained and over focus in broadening Our QX, on physicians. our of driving over our the from and approximately top X.X% growth Revenue increased QX over footprint XX accounts, accounts XX.X% five which driven commercial is utilization growth. top hospitals fiscal fiscal within in penetration
have top clear shortages burn nursing impacted perform to and and nursing accounts by our It’s impact less enabled being the Our growth larger the here. hospital’s which dedicated has a to staff therefore focus Training surgeons staff, with ability five a approaching training has efforts continuing includes a been on physicians RECELL. that and the and of local, staffing strong events has on were both staff. their tremendous advanced training Well, practice are substantial national with regional influence the use for on we our train providers. procedures,
in month. the almost to largest and practice, weekend, presentations small ABA in ABA XX hands performing quarter, we of burn held RECELL topics have RECELL of last training in the on combinations spring. addition, we burns, Meeting the in-hospital currently at In abstracts conference trainings next ABA presented largest topics sessions U.S. Region per are XXX the covered economics. XXX such and we such as Burn as synergistic Southern into the the Last approximately integration Annual Conference, with the field region and The burns, pediatric that health
despite three Burn we grill have a outages In when was on to rates, the The to are is procedure suffered to during cases to her burned. their her Conference. will Hurricane successfully able to that the to and you completing third taken where we toddler due surgeons. were later gas Today mother RECELL family remains pressure stairs Region different family week, Orleans, our high home Additional Interest patient’s to very suffered her improve and Northeast first climb save treated on to legs New all at and and in The toddler. family RECELL. pregnant husband treated quarter in were by severe all were the RECELL the burns her tell are their the with and this I’m recovering Ida, presentations floor Medical mother, and were using members who Center exploded. All they lives. University pleased carry mission burns they power to delivering
the another the important increase in fiscal that treating commonly wounds area enrollment for in reconstruction accidents of has accelerated. trial first injuries While as our from us the This such impact are focus and soft involved fourth is at materially our necrotizing, of tissue which trauma in our resection trial meant are burns. reopening soft that present quarter, patients. commercial centers not tissue currently injuries, degloving injuries we our economy same corresponding to-date and been and quarter infections originating where the The of in burns, burden
have this If of the our first Since XX and XX had quarter the XX the to-date. enrollment you pandemic. of subjects first sites we trial required up new the plan saw close Today due to the XX enrolled. year June in pivotal have of recall, subjects broad spanning XX patient with we for and slow XXXX enrolling we in we of subjects March resounding alone, XX the October geographies. In XX% enrolled enrolled been enrolled a
follow-up clinical well for a recruitment XXXX. in by holiday trends season, last complete by patients of trial, the slowdown during typical in plan an six-month current this research and Assuming XXXX, now With approval continue aiming to for of allowing the we our update. the ahead QX we’re for of end
Patients X grafting soft As to treated salesforce X or based existing we presenting address trauma trauma quickly we serviceable accounts trauma trauma hospital $XXX incrementally leverage within relationships Level expand will the market and RECELL, whether we our to a burns, market of other or and launch We center to burn trauma institution. this FDA are through routinely with on for existing surgeons we U.S. this Level of our by plan centers. SAM and into plan skin acute tissue a sales calculations, opportunity. foresee and and addressable the and addition our internal our a XXX million. for After address and same to wounds approval, have repair requirement an with reminder, injury skin for
now on in progress burns to trauma from Moving vitiligo. our and continued
disorder being is those is meaning to hosted autoimmune Of estimated October On trials U.S. online condition, XXnd, Americans. well-managed primarily is have characterized X.X the in Global X.X the up of which For stable skin underlying XXX that their vitiligo, continuing million community that deep an and autoimmune are web million population, Foundation the patient. their approximately My-Vitiligo-Team areas There underlying disease those an appear clinical spread. or disorder that not with Vitiligo to worldwide, with estimate vitiligo to attributed a our public patients the skin disease on vitiligo. by as and in patches, of including spots and pigmented webinar unfamiliar vitiligo the we target million for are a sufferers white
running and our subjects and eight of and with Today, been was GVF, trial XX As are sponsor the levels. featured pleased we’ve interest enrolled. a up XX all been of proud have sites very
I’d System completion automated is our Research this progresses We end groups scraping a in specifically, experiments the version end Medicine successful Houston rejuvenation. enrollment and with tailored of University will to and our Both the To the ongoing. the best XXXX. plan ahead. to-date Colorado, Regenerative products Methodist of continue of approval through walk vitiligo Gates proof-of-concept setting. work volumes models version vitiligo the you preliminary Work have the of for dermatology see drivers bullosa like Dermatologists us high Center to developing this gives and now for see yield Institute automate of animal or collaborations growth nursing new epidermolysis EB support patients, RECELL fully developed team at physician in in and time. methods we of opportunity, calendar of steps, will this the some of RECELL use and the the confidence proof-of-concept for skin The year. with the step by for make that calendar year staff in to
in-person engagement whether provider We virtual. or to on forward continue drive and education,
expertise shifted discussions today or support use and RECELL, Our not as RECELL from refining the to on and our staff. whether of well use the of is optimizing training focus have as
be center to continuing into penetration team commercial will burn our drive Our accounts.
of mass accounts. what that, VAC focused within believe critical those approved we in are with on penetration is centers, and We burn we a are
We XXXX that and RECELL three broader quarters driving RECELL usage. admissions. Prospective into On smaller Payment Xnd, To CMS launch shown body the surface burn our effect going plan that the Medicare one-third involve ensure XX% will have to a broader in We in of System, strategy device with cover commercial smaller Based burns or burns are mid-XXXX. to payment January nationwide which coverage all total underscore about patients. area of before for November Outpatient with less on C of our results approach, these carriers burns cost at represent a we of with procedures of overall this, be proceeding over TBSA than pilot published today XXXX. into Medicare the code sights anticipate then assigned launch will RECELL, a to in key commence
to Our More has vitiligo the our pipeline enrollment within specifically, the progress patients as XX forward. now enrolled accidents. trauma-related as should tissue initiatives XX in are we by complete about with at soft year increase move continuing recent of end, uptick which trial, excited are well trial, driven which our
we continue preclinical demonstrate the be calendar on year. to our track pipeline epidermolysis rejuvenation, We bullosa to the are proof-of-concept optimistic and about in end work by and of
steps and determining are with FDA. future forward We our path the
update treatment will and the you GLP requirements timelines to is IND for submit clear, human first accordingly. are application an data next I in once Our review goal to
PMDA to our to present partner tissue U.S. Welfare to Once and has initially, and COSMOTEC will MHLW to in coming or strategy thereafter. customers our RECELL meet to have we we COSMOTEC, feedback. burn shortly our will then advised reimbursement half Upon over have review, or footprint Labor we on will our which approval the with Authority The growth from occur broaden Health, June. of COSMOTEC Japanese soft in vitiligo data year plan for anticipate reimbursement revised we Moving launch Authority been made indications well. Health those Japanese the next Japanese progress as and Japan approval applications due across to have business. hospital on continued despite burns the through working will expect for geographic trials, in Ministry pivotal pressure summary, Health of largely In seek recent XXXX. regulatory based staffing we commercial on driver, years. a procedures our approval COSMOTEC challenges, substantial focus its first to and backlog is last approval of
and responded, headwinds and pleased advanced the front continued minds the anticipate center care in how practice near-term, keeping commercial has we driving practitioners. staffing in training our I’m While with team burn of RECELL
in to for the and Finally, progress opportunities. these substantial on a vitiligo larger the our for the financial groundswell looking trauma performance in I’ll details With interest clinical now of tissue and soft further our that, potential market turn ahead, over quarter. Michael reflect of in trials and it Michael?
